Literature DB >> 23054465

Identifying, monitoring and reducing preventable major bleeds in the hospital setting.

Deborah Caraballo1, Alex C Spyropoulos, Charles E Mahan.   

Abstract

Recent literature describes methods to reduce "preventable" hospital-acquired venous thromboembolism; however, there is a paucity of data on "preventable" bleeding. While risk assessment models exist for both thrombosis and bleeding, these concepts should be differentiated from whether the event was preventable or non-preventable. Here we describe a protocol to identify, monitor, and evaluate anticoagulation-related preventable hospital-acquired major bleeds (PHAMB). This single-center, prospective observational study with retrospective chart review was conducted in 2009 and 2010 to identify anticoagulation-related major bleeding. Eligible anticoagulation-related hospital-acquired major bleeds (HAMB) were further classified as "preventable" or "non-preventable". A total of 229 major bleed episodes were identified of which 188 were excluded due to being community-acquired or non-anticoagulation related major bleeds. Over the 2 year period, five of the 41 HAMB were classified as preventable providing a total incidence of 13 % PHAMB. Three and two of the PHAMB were due to inappropriate dosing and administration of an anticoagulant when contraindications existed, respectively. PHAMB rates decreased from 0.06 in 2009 to 0.04 per 1000 patient days in 2010 (p = 0.62) although this difference was not statistically significant. Raw incidence utilizing Joint Commission methodology demonstrated a 16.7 % rate in 2009 and an 8.7 % rate in 2010. In hospitalized patients, intervention programs may minimize the incidence of anticoagulation-related PHAMB and may maintain similar rates of preventable bleeding over time. Similar programs should be explored prospectively on a larger scale to reduce harm from anticoagulants in the hospital setting.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23054465     DOI: 10.1007/s11239-012-0819-2

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  24 in total

1.  Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators.

Authors:  Hervé Decousus; Victor F Tapson; Jean-François Bergmann; Beng H Chong; James B Froehlich; Ajay K Kakkar; Geno J Merli; Manuel Monreal; Mashio Nakamura; Ricardo Pavanello; Mario Pini; Franco Piovella; Frederick A Spencer; Alex C Spyropoulos; Alexander G G Turpie; Rainer B Zotz; Gordon Fitzgerald; Frederick A Anderson
Journal:  Chest       Date:  2010-05-07       Impact factor: 9.410

2.  Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial).

Authors:  A Michael Lincoff; John A Bittl; Neal S Kleiman; Ian J Sarembock; J Daniel Jackman; Sameer Mehta; Mark A Tannenbaum; Alan L Niederman; William B Bachinsky; J Tift-Mann; H Graham Parker; Dean J Kereiakes; Robert A Harrington; Frederick Feit; Elizabeth S Maierson; Derek P Chew; Eric J Topol
Journal:  Am J Cardiol       Date:  2004-05-01       Impact factor: 2.778

3.  Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvement.

Authors:  P Chopard; J Dörffler-Melly; U Hess; W A Wuillemin; D Hayoz; A Gallino; E B Bachli; C R Canova; J Isenegger; R Rubino; H Bounameaux
Journal:  J Intern Med       Date:  2005-04       Impact factor: 8.989

Review 4.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients.

Authors:  S Schulman; U Angerås; D Bergqvist; B Eriksson; M R Lassen; W Fisher
Journal:  J Thromb Haemost       Date:  2009-10-30       Impact factor: 5.824

5.  Venous thromboembolism pharmacy intervention management program with an active, multifaceted approach reduces preventable venous thromboembolism and increases appropriate prophylaxis.

Authors:  Charles E Mahan; Mohamed A Hussein; Alpesh N Amin; Alex C Spyropoulos
Journal:  Clin Appl Thromb Hemost       Date:  2011-09-23       Impact factor: 2.389

6.  Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.

Authors:  A Michael Lincoff; John A Bittl; Robert A Harrington; Frederick Feit; Neal S Kleiman; J Daniel Jackman; Ian J Sarembock; David J Cohen; Douglas Spriggs; Ramin Ebrahimi; Gadi Keren; Jeffrey Carr; Eric A Cohen; Amadeo Betriu; Walter Desmet; Dean J Kereiakes; Wolfgang Rutsch; Robert G Wilcox; Pim J de Feyter; Alec Vahanian; Eric J Topol
Journal:  JAMA       Date:  2003-02-19       Impact factor: 56.272

7.  Determining the in-hospital cost of bleeding in patients undergoing percutaneous coronary intervention.

Authors:  Edward F Ewen; Liping Zhao; Paul Kolm; Claudine Jurkovitz; Dogan Fidan; Harvey D White; Richard Gallo; William S Weintraub
Journal:  J Interv Cardiol       Date:  2009-02-26       Impact factor: 2.279

8.  Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25.

Authors:  Harvey D White; Eugene Braunwald; Sabina A Murphy; Ashok J Jacob; Nina Gotcheva; Leonid Polonetsky; Elliott M Antman
Journal:  Eur Heart J       Date:  2007-04-24       Impact factor: 29.983

9.  The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial.

Authors:  Keith A A Fox; Elliott M Antman; Gilles Montalescot; Stefan Agewall; Bhupathi SomaRaju; Freek W A Verheugt; Jose Lopez-Sendon; Hanoch Hod; Sabina A Murphy; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2007-05-25       Impact factor: 24.094

10.  Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.

Authors:  A K Rao; C Pratt; A Berke; A Jaffe; I Ockene; T L Schreiber; W R Bell; G Knatterud; T L Robertson; M L Terrin
Journal:  J Am Coll Cardiol       Date:  1988-01       Impact factor: 24.094

View more
  1 in total

1.  Standardized warfarin monitoring decreases adverse drug reactions.

Authors:  Lisa B E Shields; Paula Fowler; Diane M Siemens; Douglas J Lorenz; Kenneth C Wilson; Steven T Hester; Joshua T Honaker
Journal:  BMC Fam Pract       Date:  2019-11-07       Impact factor: 2.497

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.